A detailed history of Perigon Wealth Management, LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Perigon Wealth Management, LLC holds 5,678 shares of BNTX stock, worth $642,068. This represents 0.02% of its overall portfolio holdings.

Number of Shares
5,678
Previous 5,705 0.47%
Holding current value
$642,068
Previous $458,000 47.16%
% of portfolio
0.02%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

SELL
$78.36 - $124.66 $2,115 - $3,365
-27 Reduced 0.47%
5,678 $674,000
Q2 2024

Aug 02, 2024

SELL
$80.36 - $102.87 $24,349 - $31,169
-303 Reduced 5.04%
5,705 $458,000
Q1 2024

Apr 29, 2024

BUY
$88.96 - $112.35 $133,706 - $168,862
1,503 Added 33.36%
6,008 $554,000
Q4 2023

Jan 29, 2024

BUY
$90.91 - $112.75 $118,092 - $146,462
1,299 Added 40.52%
4,505 $475,000
Q3 2023

Oct 30, 2023

SELL
$98.5 - $125.08 $689 - $875
-7 Reduced 0.22%
3,206 $348,000
Q2 2023

Aug 02, 2023

SELL
$102.58 - $129.66 $718 - $907
-7 Reduced 0.22%
3,213 $346,000
Q1 2023

May 03, 2023

SELL
$122.57 - $153.67 $1,348 - $1,690
-11 Reduced 0.34%
3,220 $401,000
Q4 2022

Feb 14, 2023

SELL
$118.43 - $186.05 $592 - $930
-5 Reduced 0.15%
3,231 $485,000
Q3 2022

Dec 13, 2022

SELL
$127.65 - $183.11 $8,424 - $12,085
-66 Reduced 2.0%
3,236 $437,000
Q2 2022

Aug 11, 2022

SELL
$123.25 - $186.24 $12,448 - $18,810
-101 Reduced 2.97%
3,302 $492,000
Q1 2022

May 16, 2022

BUY
$126.25 - $231.85 $429,628 - $788,985
3,403 New
3,403 $580,000
Q3 2011

Nov 14, 2022

SELL
N/A
-66
3,236 $437,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.4B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Perigon Wealth Management, LLC Portfolio

Follow Perigon Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perigon Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perigon Wealth Management, LLC with notifications on news.